Species Tumor Type Comment for in vivo work Lead Time for in vivo studies [weeks] MB-49-luc-2 Mouse urinary bladder carcinoma C57BL/6 2
|
|
|
- Shanna Manning
- 5 years ago
- Views:
Transcription
1 America, Hershey, PA Australia, Melbourne, VIC Europe, Munich Tissue Bladder Species Tumor Type Comment for in vivo work Lead Time for in vivo studies [weeks] MB-49-luc- Mouse urinary bladder carcinoma C57BL/6 KU-7-luc- GFP Brain Mouse urinary bladder carcinoma dual labeled:ex vivo cell isolation using U87MG glioblastoma; astrocytoma also available for U87MG-luc 6 U-87 MGluc glioblastoma; astrocytoma GL61-luc Murine glioblastoma multiforme extremely bright like 4T1-luc imaging from day 0 1 Breast 4 T1 Mouse breast carcinoma Balb/C Mice
2 Breast 4 T1-luc Mouse breast carcinoma 4t1-luc- tdtomato single cell detection in vivo Mouse breast carcinoma invasion with IHC. Ex vivo cell isolation using BT-474 breast carcinoma Oestrogen dependent, hormone pellets, HER pos -4 CCL-51 Mouse breast carcinoma lung mets 4 EMT6 Mouse breast carcinoma lung mets HCC1954 breast carcinoma slow growing, SCID CB17 Mice, HER pos 6 MCF-7 breast carcinoma Estrogen dependent, hormone pellets 4 MCF-7-luc- F5 breast adenocarcinoma Estrogen dependent, hormone pellets Lung/thoracic metastasis in nude beige (Harlan) MDA-MB-31 breast adenocarcinoma, Pleural also available: MDA-MB31-luc (vp cell line) -3
3 Breast MDA- MB-31-luc- D3-H1 breast adenocarcinoma, Pleural -3 MDA- MB-31-luc- D3HLN breast adenocarcinoma, Pleural, A spontaneous lymph node metastasis from a D3H1 mammary fat pad tumor more prone to methastise -3 MDA- MB-31-luctdTomato breast adenocarcinoma, Pleural invasion with IHC. Ex vivo cell isolation using -3 MDA- MB-31-luc- GFP breast adenocarcinoma, Pleural invasion with IHC -3 MDA-MB-468 breast adenocarcinoma slow growing 60 days lead time 4 Colon Colo-05 carcinoma,colorectal induction of cachexia 3-4 Colo05-luc carcinoma,colorectal. 3-4
4 Colon CT-6 Mouse carcinoma, colorectal HCT 116 carcinoma, colorectal also available for HCT 116-luc -4 HCT 116 luc carcinoma, colorectal. -4 HT-9 adenocarcinoma, colorectal HT-9-luc-D6 adenocarcinoma; colorectal. SCID-bg: subcutaneous metastasis to lymph node and lung. Long model up to 7 weeks LoVo-6-luc-1 adenocarcinoma; colorectal. secum wall in SCID-bg (CR) MC-38 Mouse adenocarinoma SW60 carcinoma, colorectal resistant 4 Leukemia Daudi B lymphoblast, Burkitt s lymphoma (NHL) iv injection in SCID mice 4 EL4-luc Murine Lymphoma. K-56-luc chronic myelogenous leukemia (CML).
5 Leukemia LP-1 Plasmacytoma, multiple myeloma (MM) NCI-H99 Plasmacytoma, multiple myeloma (MM) bone lytic when injected in bone marrow of tibia 4 bone lytic when injected in bone marrow of tibia 4 MOLT-4-luc acute lymphoblastic leukemia Perkin- Elmer, i.p and s.c. inoculation 1- MV(4)11 acute biphenotypic B monpcytic leukemia (AML) RPMI 86 Plasmacytoma, multiple myeloma (MM) i.v. injection in NOD SCID mice 4 bone lytic when injected in bone marrow of tibia 4 Ramos Burkitt s Lymphoma iv injection in SCID- C.B-17, survival model Raji B lymphoblast, Burkitt s lymphoma (NHL) Liver iv injection in SCID mice, also available for Rajiluc clone 4 Hep 3B.1-7 hepatocellular carinoma subcutaneous and orthotopic, >90% take rate 3 HepG-luc hepatocellular carinoma HUH-7 carcinoma very variable and fast growing 3 SK-HEP-1 adenocarcinoma 4
6 Lung Carcinoma A549-luc-C8 NSCLS carcinoma, lung. SCID-bg (CR): subcutaneous, intravenous lung colonization LL/ luc Mouse Lewis Lung (C57BL6) -3 LL/-luc-M38 Mouse Lung Cancer Perkin i.v. multiple metastasis in several mouse strains, short model 5 days 1.5 NCI-H09 SCLC, Small Cell Carcinoma NCI-H460 NSCLC, pleural effusion high variability 3 also available for NCI-H460-luc -4 Melanoma Skin B16-F0 Mouse melanoa C57 Black 6 mouse B16-F10 Mouse melanoma C57 Black 6 mouse B16-F10-luc-G5 Mouse melanoma Perkin C57BL/6 Albino (Jackson Lab) iv. multiple meths. short model 13 days 1 B16-F10-luc Mouse melanoma 40 fold brighter than luc version 1 C8161 malignant melanoma metastatic clone 3
7 Melanoma Skin CHL-1 melanoma fast growing G361 malignant melanoma lung and liver metastasis, induction of cachexia 4 Pancreas L3.6pL carcinoma pancectomy in preparation -4 Pan0 Mouse carcinoma C57B16 5 MIA PaCa- carcinoma in Athymic Foxn1 nude -4 PANC-1 epithelioid carcinoma SCID mice 3-6 BxPC3-luc pancreas adenocarcinoma Perkin Prostate DU 145 prostate carcinoma slow growth rate 4 LNCaP-luc-M6 prostate carcinoma Perkin hormone sensitive SCID-bg mice, pulmonary metastases LNCaP-luc-M6 prostate carcinoma Perkin 5 fold brighter than luc version -3-3
8 Prostate PC3 prostate adenocarcinoma also as PC3 luc (vp cell line) -3 PC-3M-luc-C6 PC-3M-luc PC-3-luc prostate adenocarcinoma Perkin also as intracardiac tumor models -3 PC-3-luc-GFP prostate adenocarcinoma Thyroid SW579 squamous cell carcinoma Gastrics Perkin invasion with IHC, Ex vivo cell isolation using -3 NCI-N87-luc- GFP stomach; derived from metastatic site liver invasion with IHC, Ex vivo cell isolation using
9 Tumor vascularisation hvegf-luc/ PC3M prostate cancer Oncology/Angiogenesis reporter cell line -3 other HT1080-luc Fibrosarcoma
America, Hershey, PA Australia, Melbourne, VIC Europe, Munich
America, Hershey, PA Australia, Melbourne, VIC Europe, Munich info@vivopharm.com www.vivopharm.com Bladder MB-9-luc 2 Mouse urinary bladder carcinoma yes yes yes C57BL/6 2 Bone UMR-106 Rat osteosarcoma
Sample validation data
Bioware and Bioware Ultra oncology cell lines Sample validation data Animal models and cell injection number A549-luc-C8 (Cat. No. 119266) Model Subcutaneous Intravenous Male nu/nu Male nu/nu (Charles
Human cell line list Production of Exosome Standards - Cell Lysates
Human cell line list 2016 - Production of Exosome Standards - Cell Lysates 380 peripheral blood leukemia, pre-b cell 1301 blood leukemia, acute lymphoblastic, T cell 5637 bladder carcinoma 8305C thyroid
Juyoun Jin, D.V.M., Ph.D. Institute for Refractory Cancer Research, Samsung Medical Center
Juyoun Jin, D.V.M., Ph.D. Institute for Refractory Cancer Research, Samsung Medical Center Overview of Anticancer Drug Development Discovery Non-clinical development Clinical Trial Target Identification
HansaBioMed Catalog 2014 for Exosome Research. X. Human Cell Lines...
HansaBioMed Catalog 2014 for Exosome Research X..... HansaBioMed Catalog 2014 HUMAN CELL LINES 380 leukemia, pre-b cell 1301 leukemia, acute lymphoblastic, T cell suspension, morphology round, small cells
Supplementary Materials for
advances.sciencemag.org/cgi/content/full/2/12/e1601756/dc1 Supplementary Materials for Syrosingopine sensitizes cancer cells to killing by metformin Don Benjamin, Marco Colombi, Sravanth K. Hindupur, Charles
SHN-1 Human Digestive Panel Test results
SHN-1 Human Digestive Panel Test results HN-30 tongue HN-24 salivary gland HN-12 larynx HN-28 esophagus HN-29 stomach HN-20 pancreas HN-13 liver HN-14 gall bladder HN-27-1 duodenum HN-27-2 ileum HN-27-3
Evaluation of immunomodulatory agents in syngeneic models and immune cell phenotyping of humanized mouse models carrying patient-derived tumors
Evaluation of immunomodulatory agents in syngeneic models and immune cell phenotyping of humanized mouse models carrying patient-derived tumors Philippe Slos 2 nd Annual ICI March 15-17, 2016 Boston Introduction
Juyoun Jin, D.V.M., Ph.D. Institute for Refractory Cancer Research, Samsung Medical Center
Juyoun Jin, D.V.M., Ph.D. Institute for Refractory Cancer Research, Samsung Medical Center Animal Models for Translational Research How to apply preclinical translational research New trial concept of
Charles River Immunodeficient Models Xenograft Data Catalog
Charles River Immunodeficient Models Xenograft Data Catalog Fox Chase SCID Congenic (C.B-17 SCID) Mouse Xenograft Data askcharlesriver@crl.com www.criver.com 214, Charles River Laboratories International,
Figure S1 Time-dependent down-modulation of HER3 by EZN No Treatment. EZN-3920, 2 μm. Time, h
Figure S1 Time-dependent down-modulation of HER3 by EZN-392 HE ER3 mrna A, %Contr rol 12 No Treatment EZN-392, 2 μm 1 8 6 4 2 2 8 24 Time, h Figure S2. Specific target down-modulation by HER3 (EZN-392)
Cancer model Liver metastasis I
Cancer model Liver metastasis I H. Suemizu, M. Monnai, Y. Ohnishi, M. Ito, N. Tamaoki, and M. Nakamura. 2007. Identification of a key molecular regulator of liver metastasis in human pancreatic carcinoma
Antitumor Activity of CUDC-305, a Novel Oral HSP90 Inhibitor, in Solid and Hematological Tumor Xenograft Models
Antitumor Activity of CUDC-5, a Novel Oral HSP Inhibitor, in Solid and Hematological Tumor Xenograft Models Rudi Bao, MD/PhD April 1, 2 AACR 1th Annual Meeting 2 Experimental and Molecular Therapeutics
OBTAIN MORE INFORMATION FROM YOUR TARGET. in vivo Imaging Agents
in vivo Imaging Agents OBTAIN MORE INFORMATION FROM YOUR TARGET 2 TARGETED TO YOUR APPLICATION AND VALIDATED FOR YOUR CONFIDENCE Built around your applications choose the one that s right for you Acute
Inhibitors of Methionine Aminopeptidase-2 2 in the Treatment of Non-Hodgkin
Inhibitors of Methionine Aminopeptidase-2 2 in the Treatment of Non-Hodgkin Hodgkin s s Lymphoma Targeted Cancer Therapies William Westlin, Ph.D. Vice President, Preclinical Research Discovery of Fumagillin
Outcomes Report: Accountability Measures and Quality Improvements
Outcomes Report: Accountability Measures and Quality Improvements The FH Memorial Medical Center s Cancer Committee ensures that patients with cancer are treated according to the nationally accepted measures.
Icd 10 code lung ca with mets to bone
Icd 10 code lung ca with mets to bone 2018 ICD-10 -CM Diagnosis Code C79.9.. C79.9 is a billable/specific ICD - 10 -CM code that can be used to indicate a diagnosis. Metastasis from malignant tumor of
Chapter 3. Neoplasms. Copyright 2015 Cengage Learning.
Chapter 3 Neoplasms Terminology Related to Neoplasms and Tumors Neoplasm New growth Tumor Swelling or neoplasm Leukemia Malignant disease of bone marrow Hematoma Bruise or contusion Classification of Neoplasms
Cancer A Superficial Introduction
Cancer A Superficial Introduction Gabor Fichtinger, Queen s University Cancer some definitions Medical term: malignant neoplasm Class of diseases in which a group of cells display: uncontrolled growth
MOLECULAR PHARMACOLOGY SUPPLEMENT
MOLECULAR PHARMACOLOGY SUPPLEMENT Therapeutic targeting of a novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate to human solid tumors based on selective uptake by the proton-coupled folate
THE BURDEN OF CANCER IN NEBRASKA: RECENT INCIDENCE AND MORTALITY DATA
THE BURDEN OF CANCER IN NEBRASKA: RECENT INCIDENCE AND MORTALITY DATA Presented by: Bryan Rettig, MS Nebraska Dept. of Health & Human Services Division of Public Health May 31, 2017 Nebraska Cancer Registry
Colorectal Cancer Screening
Colorectal Cancer Screening December 5, 2017 Connecticut Cancer Partnership 14th Annual Meeting Xavier Llor, M.D., PhD. Associate Professor of Medicine Co-Director, Cancer Genetics and Prevention Program
Establishment of Human Cancer Cell Clones with Different Characteristics: A Model for Screening Chemopreventive Agents
Establishment of Human Cancer Cell Clones with Different Characteristics: A Model for Screening Chemopreventive Agents JEFFREY H. WARE 1, ZHAOZONG ZHOU 1, JUN GUAN 1, ANN R. KENNEDY 1 and LEVY KOPELOVICH
Tumour Structure and Nomenclature. Paul Edwards. Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge
Tumour Structure and Nomenclature Paul Edwards Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge Malignant Metastasis Core idea of cancer Normal Cell Slightly
List of Available TMAs in the PRN
TMA RPCI_BrainCa01 RPCI_BrCa03 RPCI_BrCa04 RPCI_BrCa05 RPCI_BrCa0 RPCI_BrCa07 RPCI_BrCa08 RPCI_BrCa15 RPCI_BrCa1 RPCI_BrCa17 RPCI_BrCa18 RPCI_BrCa19 RPCI_BrCa20 RPCI_BrCa21 RPCI_BrCa24 RPCI_BrCa25 RPCI_BrCa2
Macmillan Publications
S1 S2 S3 S3 S3 S4 S5 S6 S7 S8 S8 S9 S10 S11 S11 S12 S13 S14 S15 S17 S18 S19 Bladder Cancer: Non-Invasive, Invasive and Advanced Bone Cancer: Primary, Secondary Colon Cancer, Anal Cancer, Rectal Cancer
The main credit of this work would go to the team of cancer epidemiology department without them this report would have never come into light.
Acknowledgment The main credit of this work would go to the team of cancer epidemiology department without them this report would have never come into light. Special appreciation goes to: Prof Amal Samy
Supplemental Methods LC-MS Assay for NAD Concentration
Supplemental Methods LC-MS Assay for NAD Concentration The concentration of NAD in cells was determined by a non-validated liquid chromatography tandem mass spectrometry (LC-MS/MS) assay using 13 C 5 -NAD
2011 to 2015 New Cancer Incidence Truman Medical Center - Hospital Hill
Number of New Cancers Truman Medical Center Hospital Hill Cancer Registry 2015 Statistical Summary Incidence In 2015, Truman Medical Center diagnosed and/or treated 406 new cancer cases. Four patients
Cancer Awareness Talk ICPAK 2014
Cancer Awareness Talk ICPAK 2014 F. Chite Asirwa, MB ChB. MD. MSc. Internist. Medical Oncologist & Hematologist Asst. Professor of Medicine Division of Hematology/Oncology Indiana University Email: fasirwa@iu.edu
Cancer Genetics. What is Cancer? Cancer Classification. Medical Genetics. Uncontrolled growth of cells. Not all tumors are cancerous
Session8 Medical Genetics Cancer Genetics J avad Jamshidi F a s a U n i v e r s i t y o f M e d i c a l S c i e n c e s, N o v e m b e r 2 0 1 7 What is Cancer? Uncontrolled growth of cells Not all tumors
Take Home Quiz 1 Please complete the quiz below prior to the session. Use the Multiple Primary and Histology Rules
Take Home Quiz 1 Please complete the quiz below prior to the session. Use the Multiple Primary and Histology Rules Case 1 72 year old white female presents with a nodular thyroid. This was biopsied in
PLACE LABEL HERE. Radiation Therapy Oncology Group Phase II - SBRT - Medically Inoperable I /II NSCLC Follow-up Form. RTOG Study No.
Radiation Therapy Oncology Group Phase II - SBRT - Medically Inoperable I /II NSCLC Follow-up Form RTOG Study No. 0813 Case # Name RTOG Patient ID INSTRUCTIONS: Submit this form at the appropriate followup
Supplementary Data Supplementary Table S1. IC 50 values of ipatasertib on cell viability in cell lines with
Supplementary Data Supplementary Table S1. IC 50 values of ipatasertib on cell viability in cell lines with or without alterations in PTEN or PIK3CA. Cell Line Tissue Type Ipatasertib IC 50 (μmol/l) a
LavaCell. Fluorescent Cell Stain. (version A) Catalog No
LavaCell Fluorescent Cell Stain (version A) Catalog No. 15004 Active Motif North America 1914 Palomar Oaks Way, Suite 150 Carlsbad, California 92008, USA Toll free: 877 222 9543 Telephone: 760 431 1263
Neoplasms/Lymphoma/Leukemia
Neoplasms/Lymphoma/Leukemia Session Guidelines This is a 15 minute webinar session for CNC physicians and staff CNC holds webinars monthly to address topics related to risk adjustment documentation and
Truman Medical Center-Hospital Hill Cancer Registry 2014 Statistical Summary Incidence
Truman Medical Center-Hospital Hill Cancer Registry 2014 Statistical Summary Incidence In 2014, there were 452 new cancer cases diagnosed and or treated at Truman Medical Center- Hospital Hill and an additional
micrornas!as! Biomarkers! Landscape!
GENReports: Market & Tech Analysis micrornas!as! Biomarkers! Landscape! > Enal Razvi, Ph.D. Managing Director Select Biosciences, Inc. enal@selectbio.us! Topic Introduction and Scope! The,focus,of,this,GEN,Market,&,Tech,Analysis,Report,is,to,provide,
El contexto molecular de la sobreexpresión de PD-L1 Esther Conde Gallego, MD, PhD
El contexto molecular de la sobreexpresión de PD-L1 Esther Conde Gallego, MD, PhD Laboratorio de Dianas Terapéuticas Hospital Universitario HM Sanchinarro Madrid, Spain Contents Background PD-L1 expression
Supplementary Materials. for Garmy-Susini, et al, Integrin 4 1 signaling is required for lymphangiogenesis and tumor metastasis
Supplementary Materials for Garmy-Susini, et al, Integrin 4 1 signaling is required for lymphangiogenesis and tumor metastasis 1 Supplementary Figure Legends Supplementary Figure 1: Integrin expression
Oncology 101. Cancer Basics
Oncology 101 Cancer Basics What Will You Learn? What is Cancer and How Does It Develop? Cancer Diagnosis and Staging Cancer Treatment What is Cancer? Cancer is a group of more than 100 different diseases
Cancer in the organ donor
Cancer in the organ donor Pr Olivier Detry Dpt of Abdominal Surgery & Transplanta>on CHU Liège, University of Liege, Belgium olivier.detry@transplanta>on.be Conflicts of Interest Conflicts of Interest
Respiratory Interactive Session. Elaine Borg
Respiratory Interactive Session Elaine Borg Case 1 Respiratory Cytology 55 year old gentleman Anterior mediastinal mass EBUS FNA Case 1 Respiratory Cytology 55 year old gentleman with anterior mediastinal
Tumours in the donor: what is the risk?
Tumours in the donor: what is the risk? Pr Olivier Detry Dpt of Abdominal Surgery & Transplanta@on CHU Liège, University of Liege, Belgium olivier.detry@transplanta@on.be Financial Disclosure Research
CODING STAGE: TNM AND OTHER STAGING SYSTEMS. Liesbet Van Eycken Otto Visser
CODING STAGE: TNM AND OTHER STAGING SYSTEMS Liesbet Van Eycken Otto Visser OVERVIEW PART I Introduction What is stage? Why stage? History and publications of TNM Classification Clinical and pathologic
Supplementary Information
Supplementary Information Supplementary Figure 1. Western blotting with ERβ antibodies Full blots corresponding to Fig. 2, along with replicated experiments at different time points, different batches,
Molecular Imaging of CXCR4 Receptors
Molecular Imaging of CXCR4 Receptors.J. Wester uklearmedizinische Klinik und Poliklinik, Klinikum rechts der Isar and Institut für Radiochemie TUM Campus Garching Importance of CXCR4 and CXCL12 ypoxic
Radiology Pathology Conference
Radiology Pathology Conference Sharlin Johnykutty,, MD, Cytopathology Fellow Sara Majewski, MD, Radiology Resident Friday, August 28, 2009 Presentation material is for education purposes only. All rights
Supplementary Figure 1
Supplementary Figure 1 A B HEC1A PTEN +/+ HEC1A PTEN -/- 16 HEC1A PTEN -/- 22 PTEN RAD51 % Cells with RAD51 foci 40 -IR +IR 30 20 10 * *! TUBULIN 0 HEC1A PTEN+/+ HEC1A PTEN-/- 16 HEC1A PTEN-/- 22 C D 1.0
Type of file: PDF Size of file: 0 KB Title of file for HTML: Supplementary Information Description: Supplementary Figures
Type of file: PDF Size of file: 0 KB Title of file for HTML: Supplementary Information Description: Supplementary Figures Supplementary Figure 1 mir-128-3p is highly expressed in chemoresistant, metastatic
Cancer Metronomic Therapy Milan, February 26, 2016
Cancer Metronomic Therapy Milan, February 26, 2016 Metronomic Chemotherapy: Evolution and Development of the Concept Robert S. Kerbel, PhD Senior Scientist Sunnybrook Research Institute Professor, Dept.
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on
Icd 10 code for esophageal cancer stage 4
Icd 10 code for esophageal cancer stage 4 Search Risk factors for developing esophageal cancer include.. 150. 4 Malignant neoplasm of middle third of esophagus convert 150. 4 to ICD - 10 -CM;. Free ICD
Cancer Fundamentals. Julie Randolph-Habecker, Ph.D. Director, Experimental Histopathology Shared Resource
Cancer Fundamentals Julie Randolph-Habecker, Ph.D. Director, Experimental Histopathology Shared Resource Cancer Overview Leading cause of death in US 1.2 million diagnosed each year More common after age
TUMOR M ARKERS MARKERS
TUMOR MARKERS M.Shekarabi IUMS Definition Many cancers are associated with the abnormal production of some molecules l which h can be measured in plasma. These molecules are known as tumor markers. A good
Targeting tumour associated macrophages in anti-cancer therapies. Annamaria Gal Seminar Series on Drug Discovery Budapest 5 January 2018
Targeting tumour associated macrophages in anti-cancer therapies Annamaria Gal Seminar Series on Drug Discovery Budapest 5 January 2018 Macrophages: Professional phagocytes of the myeloid lineage APC,
Targeting Inflammation in Breast Cancer Pathogenesis
Targeting Inflammation in Breast Cancer Pathogenesis Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service Attending Physician, MSKCC Professor of Medicine, Weill Cornell Medical College August 7,
Recurrent lung cancer icd 10
Search... Recurrent lung cancer icd 10 1-10-2017 2018 ICD - 10 -CM Diagnosis unsp part of unsp bronchus or lung ; The 2018 edition of ICD - 10 -CM C34.90 became due to small cell lung cancer ; Free, official
Epidemiology in Texas 2006 Annual Report. Cancer
Epidemiology in Texas 2006 Annual Report Cancer Epidemiology in Texas 2006 Annual Report Page 94 Cancer Incidence and Mortality in Texas, 2000-2004 The Texas Department of State Health Services Texas Cancer
National Cancer Drugs Fund List - Approved
National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer
MEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site
POLICY: PG0364 ORIGINAL EFFECTIVE: 04/22/16 LAST REVIEW: 07/26/18 MEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site GUIDELINES This policy does not certify benefits or authorization
CB-1158 Inhibits the Immuno-oncology Target Arginase and Causes an Immune Mediated Anti-Tumor Response
CB-1158 Inhibits the Immuno-oncology Target Arginase and Causes an Immune Mediated Anti-Tumor Response Francesco Parlati, Ph.D. Calithera Biosciences South San Francisco, CA Arginine Depletion by Arginase
M e t a s t a t c a r c i n o m i c d
M e t a s t a t c a r c i n o m i c d 1 0 2 0 1 6 1-10-2017 Malignant melanoma of skin, unspecified. 2016 2017 2018 Billable/Specific Code. C43.9 is a billable/specific ICD - 10 -CM code that can be used
The Panel Approach to Diagnostics. Lauren Hopson International Product Specialist Cell Marque Corporation
The Panel Approach to Diagnostics Lauren Hopson International Product Specialist Cell Marque Corporation Cell Marque Rocklin, California About Cell Marque: IVD primary antibody manufacturer Distributors
BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES. Overview and Mechanism of Action Dr.
BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES Overview and Mechanism of Action Dr. Leah Klapper, CSO 88 BL-8040: Novel CXCR4 Antagonist For Hematological Cancers Indications:
For personal use only
ASX and Media release 6 April 211 Circadian s Inhibits Tumour Growth in Models of Lung, Ovarian and Prostate Cancer Data demonstrates efficacy of with other therapeutic agents in mouse models of lung,
Citi Global Healthcare Conference
Citi Global Healthcare Conference Francis Cuss, MB BChir, FRCP Chief Scientific Officer February 24, 2014 1 Forward-Looking Information During this meeting, we will make statements about the Company s
CANCER Uncontrolled Cell Division
CANCER Uncontrolled Cell Division What is cancer? Why does it occur? Where does it occur? Benign vs. Malignant? Types of Cancer (3 main groups) There are over 200 different types of cancer 1) Carcinomas
ASCO 2014 Highlights*
ASCO 214 Highlights* Investor Meeting June 2, 214 *American Society of Clinical Oncology, May 3 June 3, 214 Forward-Looking Information During this meeting, we will make statements about the Company s
Outcomes Report: Accountability Measures and Quality Improvements
Outcomes Report: Accountability Measures and Quality Improvements The s Cancer Committee ensures that patients with cancer are treated according to the nationally accepted measures. Because we are an accredited
H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS
H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS Each of you should have 37 new cards: 7 orange cards for antimetabolites 11 white cards for miscellaneous drugs (2 DNA synthesis inhibitors, 1 enzyme,
Genetic Alteration Panels
TM Genetic Alteration Panels GENETIC ALTERATION PANELS Table of Contents AKT Genetic Alteration Panel (ATCC No. TCP-1029 )...1 BRAF Genetic Alteration Panel (ATCC No. TCP-1032 )...5 EGFR Genetic Alteration
Lecture 1: Carcinogenesis
Lecture 1: Carcinogenesis Anti-cancer (oncology agents): These are perhaps the most dangerous of drugs, other than the narcotic analgesics. This is due to their toxicities. Killing or inhibiting cancer
Neoplasia 2018 lecture 11. Dr H Awad FRCPath
Neoplasia 2018 lecture 11 Dr H Awad FRCPath Clinical aspects of neoplasia Tumors affect patients by: 1. their location 2. hormonal secretions 3. paraneoplastic syndromes 4. cachexia Tumor location Even
TITLE: Crosstalk Between Cancer Cells and Bones Via the Hedgehog Pathway Determines Bone Metastasis of Breast Cancer
AD Award Number: W81XWH-07-1-0400 TITLE: Crosstalk Between Cancer Cells and Bones Via the Hedgehog Pathway Determines Bone Metastasis of Breast Cancer PRINCIPAL INVESTIGATOR: Dr. Lalita Shevde-Samantrese
Icd 10 code for lung cancer with mets to bone
Icd 10 code for lung cancer with mets to bone 1-10-2017 ICD-10 -CM Diagnosis Code. Cancer metastatic to bone ;. The majority of metastatic neoplasms to the bone are carcinomas. ICD - 10 -CM C79.51 is grouped.
Nuclear medicine in oncology. 1. Diagnosis 2. Therapy
Nuclear medicine in oncology 1. Diagnosis 2. Therapy Diagnosis - Conventional methods - Nonspecific radiopharmaceuticals cumulating in tumours - Specific radiopharmaceuticals (receptor- and immunoscintigraphy)
Broad Spectrum, Targeted Approaches To Cancer Treatment
SELECTIVELY KILLING CANCER CELLS Broad Spectrum, Targeted Approaches To Cancer Treatment Safe Harbor The presentation made during this meeting and other statements by ArQule may contain forward-looking
4/10/2018. SEER EOD and Summary Stage. Overview KCR 2018 SPRING TRAINING. What is SEER EOD? Ambiguous Terminology General Guidelines
SEER EOD and Summary Stage KCR 2018 SPRING TRAINING Overview What is SEER EOD Ambiguous Terminology General Guidelines EOD Primary Tumor EOD Regional Nodes EOD Mets SEER Summary Stage 2018 Site Specific
Metastatic esophageal cancer icd 10 code
Metastatic esophageal cancer icd 10 code Gogamz Menu Taxanes are conventional treatment for metastatic breast cancer (MBC); however, the solvents (e.g., ethanol and polyoxyethylated castor oil) employed
Neoplasia part I. Dr. Mohsen Dashti. Clinical Medicine & Pathology nd Lecture
Neoplasia part I By Dr. Mohsen Dashti Clinical Medicine & Pathology 316 2 nd Lecture Lecture outline Review of structure & function. Basic definitions. Classification of neoplasms. Morphologic features.
Biochemistry of Carcinogenesis. Lecture # 35 Alexander N. Koval
Biochemistry of Carcinogenesis Lecture # 35 Alexander N. Koval What is Cancer? The term "cancer" refers to a group of diseases in which cells grow and spread unrestrained throughout the body. It is difficult
The Role of CCR9 and Melanoma Metastasis to Small Intestine. Farin Amersi, MD Samuel Oschin Comprehensive Cancer Center Cedar Sinai Medical Center
The Role of CCR9 and Melanoma Metastasis to Small Intestine Farin Amersi, MD Samuel Oschin Comprehensive Cancer Center Cedar Sinai Medical Center BACKGROUND Melanoma is the fifth most common cancer. Estimated
PATIENT-DERIVED ORTHOTOPIC XENOGRAFTS
PATIENT-DERIVED ORTHOTOPIC ENOGRAFTS THE ONLY CLINICALLY-RELEVANT MOUSE TUMOR MODEL CRYOPRESERVATION OF PDO TUMORS DRUG DISCOVERY FOR PHARMA, BIOTECH & ACADEMIA FLUORESCENCE IMAGING & CELL LINES PRE-CLINICAL
The mir-199a/brm/egr1 axis is a determinant of anchorage-independent growth in epithelial tumor cell lines
Supplementary information Supplementary Figure -9 Supplementary Table -4 The mir-99a/brm/egr axis is a determinant of anchorage-independent growth in epithelial tumor cell lines Kazuyoshi Kobayashi, Kouhei
CANCER THERAPEUTICS: A NOVEL APPROACH
CANCER THERAPEUTICS: A NOVEL APPROACH Mary Dwyer, Ph.D. HBRI and ChemRegen, Inc. SCDMDG Meeting October 23, 212 Outline Introduction Hit, HBRI1: identification & characterization Leads, HBRI2 & HBRI3:
Prostate cancer with mets to bone icd 10. Pinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu
Search for: Search Search Prostate cancer with mets to bone icd 10 Pinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu The liver, an organ only found in vertebrates, detoxifies various metabolites,
4100: Cellular Therapy Essential Data Follow-Up Form
4100: Cellular Therapy Essential Data Follow-Up Form Registry Use Only Sequence Number: Date Received: Key Fields CIBMTR Center Number: Event date: Visit: 100 day 6 months 1 year 2 years >2 years, Specify:
Test Bank for Robbins and Cotran Pathologic Basis of Disease 9th Edition by Kumar
Link full download: http://testbankair.com/download/test-bank-for-robbins-cotran-pathologic-basis-of-disease-9th-edition-bykumar-abbas-and-aster Test Bank for Robbins and Cotran Pathologic Basis of Disease
Applications of IHC. Determination of the primary site in metastatic tumors of unknown origin
Applications of IHC Determination of the primary site in metastatic tumors of unknown origin Classification of tumors that appear 'undifferentiated' by standard light microscopy Precise classification
ACR TXIT TM EXAM OUTLINE
ACR TXIT TM EXAM OUTLINE Major Domain Sub-Domain 1 Statistics 1.1 Study design 1.2 Definitions of statistical terms 1.3 General interpretation & analysis 1.4 Survival curves 1.5 Specificity/sensitivity
NOSCAN CLINICAL MANAGEMENT GUIDELINE (CMG) AND NOSCAN CHEMOTHERAPY REVIEW (NCR) STATUS DOCUMENT May Status (G / A / R) Status (G / A / R)
Item 18-13c NOSCAN CLINICAL MANAGEMENT GUIDELINE (CMG) AND NOSCAN CHEMOTHERAPY REVIEW (NCR) STATUS DOCUMENT May 2013 BREAST CANCER MCN: Breast Disease: Breast Document ready to circulate lead to be discussed
SUPPLEMENTARY INFORMATION
doi:.38/nature8975 SUPPLEMENTAL TEXT Unique association of HOTAIR with patient outcome To determine whether the expression of other HOX lincrnas in addition to HOTAIR can predict patient outcome, we measured
Test Bank for Robbins and Cotran Pathologic Basis of Disease 9th Edition by Kumar
Link full download:https://getbooksolutions.com/download/test-bank-for-robbinsand-cotran-pathologic-basis-of-disease-9th-edition-by-kumar Test Bank for Robbins and Cotran Pathologic Basis of Disease 9th
Supplementary Material
Supplementary Material Original article in Gastric Cancer A novel splice variant of XIAP-associated factor 1 (XAF1) is expressed in peripheral blood containing gastric cancer-derived circulating tumor
Cancer Cases Treated and Results
Cancer Cases Treated and Results Below are some of the cases, from more than 30 cases we have treated so far with good results. When reading the PET/CT scans, the picture on the left is before treatment,
Cancer of Unknown Primary (CUP) Protocol
1 Department of Oncology. Cancer of Unknown Primary (CUP) Protocol Version: Document type: Document sponsor Designation Document author [ s] Designation[s] Approving committee / Group Ratified by: Date
A gene expression bar code for microarray data
A gene expression bar code for microarray data Michael J Zilliox & Rafael A Irizarry Supplementary figures and text: Supplementary Figure 1: Bar code heatmaps, dendrograms, and summaries. Supplementary
ACOS Inquiry and Response Selected Inquires CS Tumor Size/Extension Evaluation, CS Lymph Nodes Evaluation, CS Metastasis at Diagnosis Evaluation *
ACOS Inquiry and Response Selected Inquires CS Tumor Size/Extension Evaluation, CS Lymph Nodes Evaluation, CS Metastasis at Diagnosis Evaluation * CS Tumor Size/Extension Evaluation 24842 12/11/2007: Q:
Trial no. Status Phase Treatment Pre-conditioning Primary endpoints Secondary endpoints Diagnosis Sponsor
Supplemental table 1. Overview of recent clinical phase I and II trials assessing the safety and efficacy of TCR-modified T cells in cancer patients as registered at clinicaltrials.gov by September 1,